POST Online Media Lite Edition



 

Coronavirus vaccine trial by Pfizer shows mild to moderate side effects

Christian Fernsby |
Participants of a phase 3 clinical trial of American biopharmaceutical company Pfizer's coronavirus vaccine candidate were experiencing mild to moderate side effects, said the company on Tuesday.

Article continues below



Topics: PFIZER   

In a presentation to investors, Pfizer said side effects included fatigue, headache, chills and muscle pain. Some participants in the trial also developed fevers, including a few high fevers.

The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental coronavirus vaccine, BNT162b2, that Pfizer is developing with German partner BioNTech.

Over 12,000 study participants had received a second dose of the vaccine, Pfizer executives said on an investor conference call.

Depending on current infection rates, a conclusive readout on efficacy of the vaccine candidate is expected by the end of next month, according to the company.


What to read next

Moderna coronavirus vaccine enters final stage trial this month
Pfizer completes Hospira acquisition
AstraZeneca board rejects Pfizer's final proposal